More recently, our study showed that metformin treatment significantly decreased circulating PCSK9 and LDL-C levels17, which suggests the implication of PCSK9 signaling in metformin treatment for olanzapine-induced NAFLD. Here, PCSK9 is linked to metabolic dysfunction-associated steatotic liver disease.